Shares of MAP Pharmaceuticals (UNKNOWN:MAPP.DL) skyrocketed today, up nearly 60% on the news that the company was being acquired by its marketing partner Allergan (UNKNOWN:AGN.DL) for the premium of $25 per share. In this video, Motley Fool health-care analyst David Williamson tells us some of the unexpected synergies that Allergan, the company behind Botox, will be looking for in MAP Pharmaceuticals, and why this might be a good fit.

David Williamson and The Motley Fool have no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.